ecteribulin,eribulin mesylate,farletuzumab
eisai,eisai pharmaceutical,bms
['eribulin', 'farletuzumab,ecteribulin', 'farletuzumab', 'eisai']
eisai presents new findings for antibody drug conjugate farletuzumab ecteribulin at 2022 asco annual meeting 